GALENA BIOPHARMA INC's ticker is GALEXXXX and the CUSIP is 363256108. A total of 94 filers reported holding GALENA BIOPHARMA INC in Q2 2016. The put-call ratio across all filers is 0.21 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2016 | $11,000 | -15.4% | 30,125 | +4.3% | 0.00% | – |
| Q2 2016 | $13,000 | -93.5% | 28,875 | -80.5% | 0.00% | -100.0% |
| Q1 2016 | $201,000 | -10.7% | 147,875 | -3.6% | 0.00% | 0.0% |
| Q4 2015 | $225,000 | -7.8% | 153,375 | -0.6% | 0.00% | -20.0% |
| Q3 2015 | $244,000 | -6.5% | 154,369 | +0.5% | 0.01% | 0.0% |
| Q2 2015 | $261,000 | +32.5% | 153,575 | +8.5% | 0.01% | +25.0% |
| Q1 2015 | $197,000 | -7.9% | 141,575 | -0.0% | 0.00% | -20.0% |
| Q4 2014 | $214,000 | +262.7% | 141,617 | +395.6% | 0.01% | +150.0% |
| Q3 2014 | $59,000 | -43.3% | 28,575 | -15.3% | 0.00% | -33.3% |
| Q2 2014 | $104,000 | +10.6% | 33,748 | -10.6% | 0.00% | 0.0% |
| Q1 2014 | $94,000 | -39.7% | 37,748 | +20.2% | 0.00% | -40.0% |
| Q4 2013 | $156,000 | +95.0% | 31,398 | -9.8% | 0.01% | +66.7% |
| Q3 2013 | $80,000 | +19.4% | 34,798 | +14.9% | 0.00% | +50.0% |
| Q2 2013 | $67,000 | – | 30,298 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Hoxton Financial, Inc. | 50,000 | $74,000 | 0.04% |
| Alyeska Investment Group, L.P. | 1,593,277 | $2,342,000 | 0.02% |
| DUMONT & BLAKE INVESTMENT ADVISORS LLC | 31,000 | $46,000 | 0.02% |
| GROUP ONE TRADING, L.P. | 1,346,904 | $1,980,000 | 0.02% |
| Matisse Capital | 17,000 | $25,000 | 0.01% |
| COMPTON CAPITAL MANAGEMENT INC /RI | 15,000 | $22,000 | 0.01% |
| SAN FRANCISCO SENTRY INVESTMENT GROUP (CA) | 12,150 | $18,000 | 0.01% |
| EQUITEC SPECIALISTS, LLC | 19,700 | $29,000 | 0.01% |
| LADENBURG THALMANN FINANCIAL SERVICES INC. | 153,375 | $225,000 | 0.00% |
| OPPENHEIMER & CO INC | 94,300 | $138,000 | 0.00% |